JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



First published online February 11, 2010, 10.2967/jnumed.109.072819
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.109.072819v1
51/3/397    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heute, D.
Right arrow Articles by Virgolini, I. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heute, D.
Right arrow Articles by Virgolini, I. J.
Journal of Nuclear Medicine Vol. 51 No. 3 397-400
© 2010 by Society of Nuclear Medicine
doi: 10.2967/jnumed.109.072819

Brief Communication

Response of Recurrent High-Grade Glioma to Treatment with 90Y-DOTATOC

Dirk Heute1, Herwig Kostron2, Elisabeth von Guggenberg1, Shota Ingorokva2, Michael Gabriel1, Georg Dobrozemsky1, Günther Stockhammer3 and Irene J. Virgolini1

1 Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; 2 Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria; and 3 Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria

Correspondence: For correspondence or reprints contact: Irene J. Virgolini, Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. E-mail: irene.virgolini{at}i-med.ac.at

The treatment of patients with high-grade malignant glioma still represents an unsolved clinical problem. We report the treatment of 3 patients who had World Health Organization grade IV recurrent glioblastoma: a 23-y-old woman and 2 men aged 61 and 62 y. Methods: All 3 patients were treated with the somatostatin receptor radiopharmaceutical 90Y-labeled [1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid0-D-Phe1,Tyr3]octreotide (DOTATOC). A cumulated dose of 1.7–2.2 GBq given in 3 or 4 cycles was locally injected into a previously implanted catheter system. Results: Treatment was successful in all 3 patients, with only minor side effects reported. After treatment, MRI and PET showed complete remission in one patient and partial remission in the other patients. These findings correlated well with clinical improvement and improved quality of life. Conclusion: Receptor-mediated radionuclide therapy by locally injected 90Y-DOTATOC is feasible and well tolerated. This approach represents an attractive strategy for the treatment of locally recurring or progressing glioblastoma.

Key Words: glioblastoma • intracavitary treatment • 90Y-DOTATOC

COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2010 51: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2010 by the Society of Nuclear Medicine.